Trial Profile
Proof-of-concept study investigating AEZS 108 in pancreatic cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2010
Price :
$35
*
At a glance
- Drugs Zoptarelin doxorubicin (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 15 Dec 2010 This trial is expected to be initiated in 2011, according to an Aeterna Zentaris media release.
- 15 Dec 2010 New trial record